A Phase I, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of AZD1163 Administered as Single and Multiple Ascending Doses in Healthy Volunteers
Latest Information Update: 30 Jun 2025
At a glance
Most Recent Events
- 24 Jun 2025 Planned End Date changed from 23 Dec 2025 to 28 Jan 2026.
- 24 Jun 2025 Planned primary completion date changed from 23 Dec 2025 to 28 Jan 2026.
- 24 Jun 2025 Status changed from recruiting to active, no longer recruiting.